logo
Plus   Neg
Share
Email

Biogen's Data Shows Improved Gastrointestinal Tolerability With Vumerity

Biogen Inc. (BIIB) said that the Phase 3 EVOLVE-MS-2 study demonstrated improved patient-assessed gastrointestinal or GI tolerability of Vumerity, a new FDA-approved treatment for relapsing forms of multiple sclerosis or MS, compared to Tecfidera.
Results for the primary endpoint show patients treated with Vumerity self-reported 46 percent fewer days with intensity scores of =2 on the Individual Gastrointestinal Symptom and Impact Scale (IGISIS), compared to Tecfidera.

The EVOLVE-MS-2 results also indicate that compared to TECFIDERA, VUMERITY-treated patients had lower discontinuations due to GI adverse events (AEs) (0.8 percent vs. 4.8 percent).

VUMERITY is now available in the U.S. for relapsing forms of MS.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A California court ruled that Uber and Lyft must classify their drivers as employees in a preliminary injunction issued on Monday. However, the court has stayed the injunction for 10 days to allow the ride-hailing service providers to appeal the decision. Hyundai Motor has launched a new IONIQ brand dedicated to battery electric vehicles, as the automaker is accelerating its efforts to gain a share in the fast-growing global EV market. Under the IONIQ brand, Hyundai plans to introduce three new dedicated electric vehicle models over the next four years. Hyundai is South Korea's largest automaker. Amazon.com, Inc. is in talks with mall operator Simon Property Group, Inc. to use the abandoned anchor departmental stores of JC Penny and Sears at their malls as fulfillment centers, reports said. This is expected to help the e-commerce giant in boosting their last mile delivery, which is the last leg of the delivery process.
Follow RTT